Retreatment with venetoclax and rituximab in CLL patients achieved 100% response rates and prolonged progression-free ...

A Maui Derm 2026 session explored advancements in pediatric dermatology, emphasizing precision medicine and targeted therapies for children.

Dr. Hirsch discusses the promising efficacy and safety of cevertinib for HER2-mutant non-small cell lung cancer, highlighting ...

The CDC's revised schedule reduces routine vaccines from 17 to 11 diseases, with some vaccines now for high-risk groups or ...

The American Academy of Pediatrics (AAP) released its 2026 child and adolescent immunization schedule, which continues to ...

D-VRd is the only quadruplet regimen approved for patients with newly diagnosed multiple myeloma, irrespective of transplant ...

Psoriatic arthritis (PsA) affects roughly 30% of patients with psoriasis, yet no 2 cases look alike, says Philip Mease, MD, director of rheumatology and research, Providence Swedish Medical Center, ...

Speakers delved into innovative strategies in skin tumor management, focusing on chemotherapies, patient risk assessment, and evolving treatment protocols.

Large language models (LLMs) can provide generally accurate and patient-appropriate information for common postoperative Mohs surgery questions, particularly when guidance is straightforward and ...

CMS has announced that the new cycle of drug price negotiations by Medicare will include big-name drugs for diabetes and HIV/AIDS, as well as Botox injections. 1,2 The 15 high-cost prescription drugs ...

Explore how evolving treatment strategies and biomarkers are transforming the management of HER2-positive breast cancer in clinical practice.

It seems there is no text provided for summarization. Please share the content you'd like summarized, and I'll be happy to help!